Human mesenchymal stem cells for the management of systemic sclerosis. Systematic review

Escobar-Soto, Carlos-Hugo; Mejia-Romero, Rossana; Aguilera, Natalia; Alzate-Granados, Juan Pablo; Mendoza‐Pinto, Claudia; Munguía‐Realpozo, Pamela; Méndez‐Martínez, Socorro; Garcı́a-Carrasco, Mario; Rojas-Villarraga, Adriana

doi:10.1016/j.autrev.2021.102831

Cited by 10 publications

(2 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mesenchymal stromal cells (MSC) are potential tools to treat vascular dysfunction, due to their immunosuppressive, antifibrotic and proangiogenic properties (215)(216)(217). Although MSCs from SSc patients display reduced capacity to differentiate into ECs in vitro (218), intramuscular injections of autologous MSCs reduced necrotic areas in one SSc patient with critical limb ischemia (219).…”

Section: Other Cell Types Used For Ssc-vasculopathy: Bone Marrow Mesenchymal Stromal Cellsmentioning

confidence: 99%

Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies

Zanin-Silva

Santana-Gonçalves

Kawashima-Vasconcelos

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Systemic Sclerosis (SSc) is an autoimmune disease marked by dysregulation of the immune system, tissue fibrosis and dysfunction of the vasculature. Vascular damage, remodeling and inadequate endothelial repair are hallmarks of the disease. Since early stages of SSc, damage and apoptosis of endothelial cells (ECs) can lead to perivascular inflammation, oxidative stress and tissue hypoxia, resulting in multiple clinical manifestations. Raynaud's phenomenon, edematous puffy hands, digital ulcers, pulmonary artery hypertension, erectile dysfunction, scleroderma renal crisis and heart involvement severely affect quality of life and survival. Understanding pathogenic aspects and biomarkers that reflect endothelial damage in SSc is essential to guide therapeutic interventions. Treatment approaches described for SSc-associated vasculopathy include pharmacological options to improve blood flow and tissue perfusion and, more recently, cellular therapy to enhance endothelial repair, promote angiogenesis and heal injuries. This mini-review examines the current knowledge on cellular and molecular aspects of SSc vasculopathy, as well as established and developing therapeutic approaches for improving the vascular compartment.

show abstract

Section: Other Cell Types Used For Ssc-vasculopathy: Bone Marrow Mesenchymal Stromal Cellsmentioning

confidence: 99%

Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies

Zanin-Silva

Santana-Gonçalves

Kawashima-Vasconcelos

et al. 2021

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Mesenchymal stem cells (MSCs) are also attracting attention in regenerative medicine, such as the treatment of intractable skin ulcers in systemic sclerosis (SSc) using the differentiation ability of MSCs into vascular endothelial cells and the treatment of systemic lupus erythematosus (SLE) using the immunosuppressive effect of MSCs (3,4). Endothelial progenitor cells (EPCs) contained in the mononuclear cell fraction of bone marrow and peripheral blood also can differentiate into vascular endothelial cells (5), and their application to vascular regeneration therapy is being attempted.…”

Section: Introductionmentioning

confidence: 99%

Current State and Issues of Regenerative Medicine for Rheumatic Diseases

Yoshimi

Nakajima

2022

Front. Med.

View full text Add to dashboard Cite

The prognosis of rheumatic diseases is generally better than that of malignant diseases. However, some cases with poor prognoses resist conventional therapies and cause irreversible functional and organ damage. In recent years, there has been much research on regenerative medicine, which uses stem cells to restore the function of missing or dysfunctional tissues and organs. The development of regenerative medicine is also being attempted in rheumatic diseases. In diseases such as systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and rheumatoid arthritis, hematopoietic stem cell transplantation has been attempted to correct and reconstruct abnormalities in the immune system. Mesenchymal stem cells (MSCs) have also been tried for the treatment of refractory skin ulcers in SSc using the ability of MSCs to differentiate into vascular endothelial cells and for the treatment of systemic lupus erythematosus SLE using the immunosuppressive effect of MSCs. CD34-positive endothelial progenitor cells (EPCs), which are found in the mononuclear cell fraction of bone marrow and peripheral blood, can differentiate into vascular endothelial cells at the site of ischemia. Therefore, EPCs have been used in research on vascular regeneration therapy for patients with severe lower limb ischemia caused by rheumatic diseases such as SSc. Since the first report of induced pluripotent stem cells (iPSCs) in 2007, research on regenerative medicine using iPSCs has been actively conducted, and their application to rheumatic diseases is expected. However, there are many safety issues and bioethical issues involved in regenerative medicine research, and it is essential to resolve these issues for practical application and spread of regenerative medicine in the future. The environment surrounding regenerative medicine research is changing drastically, and the required expertise is becoming higher. This paper outlines the current status and challenges of regenerative medicine in rheumatic diseases.

show abstract

Umbilical cord mesenchymal stem cells transplantation in patients with systemic sclerosis: a 5-year follow-up study

Alip,

Wang,

Zhao

et al. 2024

Clin Rheumatol

View full text Add to dashboard Cite

Human mesenchymal stem cells for the management of systemic sclerosis. Systematic review

Cited by 10 publications

References 63 publications

Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies

Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies

Current State and Issues of Regenerative Medicine for Rheumatic Diseases

Umbilical cord mesenchymal stem cells transplantation in patients with systemic sclerosis: a 5-year follow-up study

Contact Info

Product

Resources

About